**Quarterly activities report for April – June 2025**

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

**Monitoring of GMO Dealings involving Intentional Release (DIR)**

During the quarter the OGTR did not inspect any organisations conducting GMO dealings involving intentional release.

**Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical trials**

During the quarter the OGTR inspected **two** organisations holding certified facilities (**Table 1**).

Table 1 – Summary of organisations and facility types that the OGTR inspected for the April – June 2025 quarter.

| **Organisation** | **Physical Containment (PC) level**  | **Number of facilities monitored** |
| --- | --- | --- |
| DST Group Melbourne | PC2 LaboratoryPC3 Facility | 21 |
| The University of Sydney | PC2 LaboratoryPC2 Animal FacilityPC2 InvertebratePC2 Aquatic | 13312 |
| **Total** |  | **22** |

**Practice Reviews, Audits and Investigations**

The Monitoring and Compliance section may initiate Practice Reviews in response to observations made during earlier monitoring activities, or to follow up on incident reports. The objective is to determine if licence conditions can be, and are being, effectively implemented.

During the April – June 2025 quarter, the OGTR did not conduct Practice Reviews or investigations. The audit of Monash University in Victoria is underway, and the findings will be included in the Gene Technology Regulator’s Annual Report upon completion.

Audits of seed breeding companies were conducted in Queensland reviewing their quality assurance processes as part of the OGTR Low Level Presence Strategy. These audits of the industry are ongoing and will be reported in the Annual Report.

**Monitoring and Compliance Findings**

Findings from routine monitoring, auditing, investigations, and related enforcement activities, will be provided in the Regulator’s Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.